Treatment with buprenorphine prior to EcoHIV infection of mice prevents the development of neurocognitive impairment,Journal of Leukocyte Biology

当前位置： X-MOL 学术 › J. Leukoc. Biol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment with buprenorphine prior to EcoHIV infection of mice prevents the development of neurocognitive impairment
Journal of Leukocyte Biology ( IF 3.6 ) Pub Date : 2020-06-24 , DOI: 10.1002/jlb.5ab0420-531r
Matias Jaureguiberry-Bravo ₁ , Jennifer Kelschenbach ₂ , Aniella Murphy ₁ , Loreto Carvallo ₂ , Eran Hadas ₂ , Lydia Tesfa ₃ , Travis M Scott ₄ , Monica Rivera-Mindt ₄ , Chinazo O Cunningham ₅ , Julia H Arnsten ₅ , David J Volsky ₂ , Joan W Berman _{1,

3}

Affiliation

Approximately 15–40% of people living with HIV develop HIV‐associated neurocognitive disorders, HAND, despite successful antiretroviral therapy. There are no therapies to treat these disorders. HIV enters the CNS early after infection, in part by transmigration of infected monocytes. Currently, there is a major opioid epidemic in the United States. Opioid use disorder in the context of HIV infection is important because studies show that opioids exacerbate HIV‐mediated neuroinflammation that may contribute to more severe cognitive deficits. Buprenorphine is an opioid derivate commonly prescribed for opiate agonist treatment. We used the EcoHIV mouse model to study the effects of buprenorphine on cognitive impairment and to correlate these with monocyte migration into the CNS. We show that buprenorphine treatment prior to mouse EcoHIV infection prevents the development of cognitive impairment, in part, by decreased accumulation of monocytes in the brain. We propose that buprenorphine has a novel therapeutic benefit of limiting the development of neurocognitive impairment in HIV‐infected opioid abusers as well as in nonabusers, in addition to decreasing the use of harmful opioids. Buprenorphine may also be used in combination with HIV prevention strategies such as pre‐exposure prophylaxis because of its safety profile.

中文翻译：

在小鼠感染 EcoHIV 之前使用丁丙诺啡治疗可预防神经认知障碍的发生

尽管抗逆转录病毒治疗取得了成功，但大约 15-40% 的 HIV 感染者会出现与 HIV 相关的神经认知障碍 (HAND)。没有治疗这些疾病的疗法。 HIV 在感染后早期就进入中枢神经系统，部分是通过受感染单核细胞的迁移。目前，美国存在严重的阿片类药物流行病。 HIV 感染背景下的阿片类药物使用障碍很重要，因为研究表明阿片类药物会加剧 HIV 介导的神经炎症，从而可能导致更严重的认知缺陷。丁丙诺啡是一种阿片衍生物，通常用于阿片激动剂治疗。我们使用 EcoHIV 小鼠模型来研究丁丙诺啡对认知障碍的影响，并将其与单核细胞迁移到中枢神经系统的相关性。我们表明，在小鼠 EcoHIV 感染之前进行丁丙诺啡治疗可防止认知障碍的发生，部分原因是通过减少大脑中单核细胞的积累。我们认为丁丙诺啡除了减少有害阿片类药物的使用外，还具有一种新的治疗益处，可以限制感染艾滋病毒的阿片类药物滥用者和非滥用者神经认知障碍的发展。由于其安全性，丁丙诺啡还可与艾滋病毒预防策略（例如暴露前预防）结合使用。

更新日期：2020-06-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11